Basic HTML Version
29
to perform. The collection can be performed after either
natural birth or caesarean section.
The risk of viral infection in the stored stem cells is con-
sidered extremely low if adequate screening procedures
are performed pre-birth. For this reason international
accreditation standards Lazaron requires the patient to
undergo a series of blood tests between two and three
weeks prior to delivery date.
It is reported that in terms of current medical knowledge,
the probability of an infant requiring stem cells for a
bone marrow transplant is in the order of 1:2700. Umbili-
cal cord stem cells are also the most suitable for donat-
ing to other family members, including the parents.
The exponential pace of international research in stem
cell technology and its application has resulted in many
new therapies being identified on an ongoing basis. The
use of stem cells derived from the umbilical cord of new
born babies is fast becoming the de facto standardWhile
clinical stem cell applications are still limited, the impor-
tance of cord blood stem cell storage is undeniable and
cord blood stem cell banking is increasing world wide.
In addition to continuing to penetrate the stem cell stor-
age market, Lazaron will increasingly focus on the devel-
opment of therapy centres which would provide outpa-
tient treatment of patients utilising stem cell technology.
The company anticipates two specific markets which are
•
Post operative therapy to improve recuperation, and
•
Sports medicine also directed at improved
recuperation.
As a separate and independent division of Lazaron will
also further the research in animal stem cell therapies in
conjunction with various universities. The objective is to
commercialise the intellectual property which has been
under development for the past four years. Lazaron in-
tends to offer regenerative veterinary cell replacement
therapy to the racehorse, competitive sport horse and
domestic pet markets. The efforts will initially be aimed
at tendon and cartilage regeneration. This will build
company capacity and expertise, which will benefit our
future clients. Trials have shown a 300% acceleration
in healing in animal tendon and related injuries with a
corresponding improvement in strength post healing.
The technology is practical and easy to apply.
Post Period
Corporate action was instituted in November which in-
cluded;
•
A rights offer to shareholders at share price of R0.01
and an allocation of 9 shares to every 1 held on
Friday 18th November
•
A section 112 disposal of assets from Lazaron for on
sale into Cryo-Save SA
•
A share swap offer whereby Lazaron shareholders
may acquire 1 JDH share for every 5 shares held in
Lazaron
To be what we are, and to become what we are
capable of becoming, is the only end of life.
- Robert Louis Stevenson